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Abstract
Background: Co-infection with Mycobacterium tuberculosis remains a leading cause of morbidity and mortality among HIV
infected individuals especially in developing countries. Early initiation of cART in these patients when CD4+ T cell count is
less than 200cells/mm3 has reduced disease progression and mortality. However for patients with higher CD4+ T cell
counts greater than 350cells/mm3 evidence is conflicting. In this study we seek to evaluate the effectiveness of cART in
reducing mortality among TB-HIV co-infected patients with CD4 + T cells above 350cells/mm3 at the time of TB diagnosis.
Method: In a retrospective cohort study we analyzed 337 HIV-TB co-infected patients with CD4+ T cells above 350cells/
mm3 at baseline who were diagnosed between 2006 and 2012 in the southern province of Zambia. The primary outcome
was all-cause mortality. We estimated the effect of cART by comparing survival according to cART and controlling for
differential loss to follow-up.
Results: Of the 257 patients on cART, 22 died (9 %) and 20 (8 %) were lost to follow-up; of 80 patients not on cART, 20
died (25 %) and 19 (24 %) were lost to follow-up. Patients treated with cART had better survival compared to those not
treated (P< 0 · 0001, log-rank test). In a proportional hazard regression adjusting for Cotrimoxazole, the risk of death was
reduced by 78 % with cART (95 % CI: 0 · 47, 0 · 91). In a propensity score analysis, the effect of cART was still beneficial.
Conclusion: In patients with HIV-associated TB and CD4+ T cells above 350cells/mm3, treatment with cART reduced
mortality for up to 4 years as compared to no cART and was associated with better retention in care.
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Background
Co-infection with Mycobacterium tuberculosis remains a
leading cause of morbidity and mortality among Human
Immunodeficiency Virus (HIV) infected individuals espe-
cially in developing countries [1, 2]. HIV-infected individuals
are not only at high risk of developing Tuberculosis (TB),
but also at increased risk for severe forms of the disease, re-
current disease and high mortality [3, 4]. The use of con-
tinuation Anti-Retroviral Treatment (cART) has reduced
disease progression and death among patients with HIV in-
fection, but the optimal time for initiating therapy is uncer-
tain for patients co-infected with TB [5, 6]. For TB patients
with CD4+ T cell counts lower than 200 cells/ mm3, the ef-
fects of cART on survival are convincing, [7–10] but for pa-
tients with CD4+ T cell counts above 350 cells/mm3, the
effects of cART on survival are conflicting [11].
Some studies have concluded that early initiation of
cART during treatment for TB improves survival among
patients, [7–10] whereas other studies have not found
this same benefit [11]. Based on the best available evi-
dence and expert opinion, the World Health Organization
(WHO) issued guidelines in 2009 recommending that
cART should be initiated for all HIV-infected patients with
active TB disease within the first 8 weeks of starting TB
treatment regardless of the CD4+ T cell count [12]. Apart
from the effects on mortality early initiation of cART in* Correspondence: simon.mutembo@gmail.com
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TB-HIV co-infected patients reduces the incidence of tu-
berculosis across all CD +T cell count levels [13].
The conflicting evidence concerning the optimal timing
of cART is based on randomized controlled trials (RCTs)
measuring efficacy under ideal, controlled settings that are
difficult to replicate in clinical settings [14]. Therefore, an
estimate of individual effectiveness will provide a better
idea of how TB-HIV co-infected patients with a preserved
immunity (CD4+ T count above 350cells/mm3) respond
to cART under programmatic conditions [15].
We used routinely collected clinical data from the TB
and HIV treatment program in the southern part of
Zambia to evaluate effectiveness of cART in reducing
mortality among TB-HIV co-infected patients with CD4
+ T cells above 350cells/mm3 at the time of TB diagnosis
and TB treatment initiation. We also explored the effect
of cART on other programmatic outcomes such as loss
to follow up using appropriate statistical methods to ad-
dress potential bias of the observational program data.
Methods
Overview
Using a retrospective cohort study design, we evaluated
TB treatment response and survival in 337 HIV-infected
TB patients who had CD4+ T cells of 350cells/mm3 or
greater at the time of TB diagnosis or TB treatment ini-
tiation (baseline CD4+ T count).
Study setting and procedures
The data was collected from the southern province of
Zambia between January 2012 and June 2012. The Ministry
of Health in Zambia started implementing the WHO guide-
line of treating all TB HIV co-infected patients at the begin-
ning of 2010 [16]. Between 2006 and 2010 HIV patients
with CD4+ T count less than 200 cells/mm3 diagnosed with
TB were started on cART between 2 and 8 weeks after initi-
ation of TB therapy after being assessed to be clinically
stable while on TB treatment [17]. For patients with CD4+
count above 350-cells/mm3 cART was differed until com-
pletion of TB therapy. In 2010 the guidelines were updated
and required that all TB-HIV co-infected patients be initi-
ated on TB therapy followed by cARTas soon as possible re-
gardless of the CD4+T count [12]. However, individual
physician practice varied and TB patients were started on
cART based on clinical indication as far back as 2006, even
with CD4+ Tcounts above 350cells/mm3.
Patient data were abstracted from the TB registers, cART
registers and files at Livingstone General Hospital, Monze
Mission Hospital, Choma Hospital, Maramba clinic and
Mazabuka District Hospital. This analysis included data for
both in-patient and out-patient care. The inclusion criteria
were: diagnosis of TB by a clinician with or without a spu-
tum smear positive result where full course TB medication
was prescribed, HIV seropositive, CD4+ T counts of 350
cells/mm3 or greater at time of TB diagnosis (at base-
line), and age of 15 years and older. Patients were ex-
cluded if they were already on cART at the time of TB
diagnosis or had incomplete information available in
the medical records. We cross-linked TB clinic with
ART clinic records to identify eligible patients.
Medical records were reviewed and data abstracted
using standardized data collection forms. The main out-
come for this study was all-cause mortality. Death and
date of death were ascertained through medical records.
When the date of death was not available we used the
last date of contact with the clinic as the date evaluated.
Patients who were alive at the end of the study period
were censored on that date; patients lost to follow-up
were censored on the date they were last seen in the
clinic or the last drug refill date. The secondary out-
comes of the study were completion and cure, default
on therapy, and TB treatment failure. Standard defini-
tions according to the National TB Program (NTP)
based on WHO guidelines were applied [1].
Exposure and outcome measures
Our main exposure was initiation of cART during TB
treatment. Since this was a retrospective cohort study,
the decision to initiate therapy was made by the treat-
ing clinician and patient, and not influenced by study
investigators. The start date and initial cART regimen
were recorded from medical records in the cART
clinics. Patient demographic information, clinical and
laboratory data were extracted from patient files; the
data included stage of HIV disease, Cotrimoxazole
prophylaxis, WHO stage of HIV infection, performance
status, and hemoglobin.
Statistical analysis
Observed survival was defined as the time of the initi-
ation of anti-tuberculosis treatment until death or cen-
soring. Separate survival distributions were estimated
using Kaplan-Meier methods for patient receiving cART
and those not receiving cART; survival distributions
were compared using log-rank test. Adjusted Cox pro-
portional hazards models were used to estimate the haz-
ard ratios for death among patients treated with cART
versus those not treated with cART. The proportional
hazards assumption was tested using graphical methods;
no violations of this assumption were found.
Because of the retrospective nature of data collection,
we performed a sensitivity analysis to evaluate con-
founding by indication and the effect of loss to follow-
up. To address the confounding by indication, we per-
formed a propensity score analysis. Using a logistic re-
gression analysis, we calculated the expected probability
of starting cART for each member of the cohort using a
full list of covariates and interactions; this probability
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was considered the propensity score for starting cART. Using
this score, we matched patients who started cART with pa-
tients who did not start cART in a one-to-one manner ac-
cording to the propensity scores. We were able to match 66
pairs of patients (N= 132). We then compared the clinical
characteristics between the matched pairs to ensure balance.
In this propensity matched cohort, we repeated the Kaplan-
Meier analysis to estimate covariate adjusted mortality be-
tween the groups used an adjusted Cox proportional hazards
model to examine the overall effect of cART on survival.
To evaluate the effect of bias due to the loss to follow-up,
we evaluated two extreme scenarios. In the first scenario, we
assumed that all patients who were lost to follow-up sur-
vived until the end of the observation period (August 2012);
in the second, we assumed that all individuals lost to follow-
up died within 90 days of the date last seen. Survival distri-
butions and hazard ratios for each scenario were compared
with the main study results to determine whether study con-
clusions would be altered in these two scenarios. All statis-
tical analysis was performed with SAS software version 9.4
(Cary, NC, USA) and Kaplan Meier curves were plotted
with the survminer package in R-statistical software [18, 19].
Results
We identified a total of 4452 patients in the TB registers
who were TB and HIV co-infected between January 2006
and August 2012. We cross-linked them with the cART
Clinic registers. After applying the inclusion and exclusion
criteria, we identified 337 patients who had CD4 + T cell
count greater than 350 cells/mm3 who were eligible for
the analysis; 4015 patients were excluded because of
CD4+ T cell count less than 350 cells/mm3 and/or had
insufficient clinical data (Fig. 1).
Of these 337 patients, 257 (76 %) were started on
cART during TB treatment and 80 (24 %) were never
started on cART. The patients in the two cohorts were
clinically similar in terms of age, sex, hemoglobin level,
weight CD4+ T cell count and functional state (Table 1).
The median CD4+ T cell count in the patients on cART
was 465 cells/mm3 (interquartile range: 391, 576) and in
patients not on cART, 468 cells/mm3 (interquartile
range: 397, 611). There were 173 patients on Cotrimoxazole
prophylaxis in the cohort on cART (67 %) as compared to
17 for those who were not started on cART (21 %).
The median duration of follow-up was 906 days (inter-
quartile range: 358, 1543) in the cohort on cART and
212 days (interquartile range: 109, 652) in the cohort not
on cART. In the cohort of patients on cART, 20 patients
(7 · 8 %) were lost to follow-up and 26 patients (10 %) were
transferred to another health facility (Fig. 1), whereas
among the 80 patients who were never on cART, 19 (24 %)
were lost to follow-up and 12 (15 %) transferred care.
During follow-up, 22 patients died in the cART cohort
whereas 20 died in the cohort without cART. Patients on
cART experienced a better overall survival compared to pa-
tients not on cART (Fig. 2a; P value < 0 · 0001, log-rank test).
The 1-year survival proportion in patients on cART was 0 ·
95 and for patients not on cART was 0 · 81. In a multivariable
Cox proportional hazards analysis, the risk of death among
patients on cART was reduced by 78 % compared to patients
not on cART (adjusted HR=0 · 22; 95 % CI 0 · 09, 0 · 53),
even when controlling for Cotrimoxazole prophylaxis and
cure of TB at end of therapy. Of note, Cotrimoxazole use was
an independent predictor of survival and reduced the risk of
death by 97 % (adjusted HR=0 · 03; 95 % CI 0 · 01, 0 · 26;
Table 2). Survival times used to perform the survival analysis
are provided as Additional file 1 (KM_cART.csv).
In a propensity score analysis, 66 pairs of cART
treated and untreated patients were closely matched
based on the probability of receiving cART. The mean
difference in propensity score was -0 · 0045 (standard de-
viation = 0 · 015), and the distribution of differences was
normally distributed. Key prognostic factors for death
were balanced between the two groups. Cotrimoxazole
treatment was comparable between groups as 24 % of
each group received it. When matching for the propensity
score, the survival distributions over 4 years differed be-
tween the cART treated and untreated cohorts, as in the
overall analysis. The 1-year survival proportion in the
cART treated group remained better than the cART un-
treated group 0 · 87 vs. 0 · 80 (Fig. 2b, log-rank test 0 · 08).
Early survival during treatment for TB was similar be-
tween groups; however, the survival curve separated
after about 1 year. In a multivariable Cox regression
model of the matched pairs, cART reduced mortality by
63 % (HR = 0 · 37, 95 % CI: 0 · 15, 0 · 93) when adjusting
for independent predictors of Cotrimoxazole and TB
cure (Table 2).
In a sensitivity analysis to assess the effect of differen-
tial loss to follow-up, we found that the results were not
Fig. 1 Summary of study enrolment, analysis and outcomes of the
2 cohorts
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altered in the two divergent scenarios. When we as-
sumed that patients lost to follow-up survived until the
end of the study, the reduction in mortality was 59 %
(adjusted HR = 0 · 41, 95 % CI 0 · 18, 0 · 92; Table 3).
When we assumed that patients lost to follow-up died
within 90 days of their last recorded clinic visit, the re-
duction in mortality was 72 % (adjusted HR = 0 · 28,
95 % CI 0 · 16, 0 · 49; Table 3). In both scenarios, the sur-
vival distributions between cART treated and untreated
patients differed as in the overall analysis.
Discussion
This study showed that initiation of cART during TB
treatment in HIV and TB co-infected patients reduced
all-cause mortality by over 60 % among patients with
CD4+ T cell counts of more than 350 cells/mm3. The
effect was durable, lasting up to 4 years. We also
found that Cotrimoxazole was an independent pre-
dictor of survival and lowered the risk of death by
90 % in these patients, consistent with previous stud-
ies [20]. This study is unique because it provides an
estimate of individual effectiveness from the long-
term survival experience of African patients with
HIV-associated TB and relatively preserved immunity.
The findings are likely to be applicable to other HIV
seropositive patients in other settings in Africa be-
cause this analysis is based on program data. The re-
sults also reinforce WHO recommendations to initiate
cART in TB-HIV co-infected patients concurrently
with TB treatment.
Since the advent of antiretroviral therapy in 1996, a
central question in HIV care has been when to start
treatment [17]. The answer to this question has evolved
over time, but today there is convincing evidence from
two large, independent studies which show that survival
is maximized when cART is started early in the course
of HIV infection [5, 6]. As this line of thought evolved,
so did the recommendations for cART during TB treat-
ment. All-cause mortality is high during the first year
after TB treatment, even when treated with appropriate
anti-tuberculosis medications. When cART was added
to TB treatment regimens, mortality reduced among pa-
tients with advanced immunosuppression [7–11].
On the hand the question of when to start cART dur-
ing TB has not been conclusively addressed, especially
in TB patients with preserved immunity as measured by
CD4+ T cell count. In published clinical trials, cART
confers a survival benefit among TB patients when
started as early as possible during TB treatment among
patients with CD4+ T cell counts less than 250cells/
mm3 [8–10]. However the survival benefit of cART
among patients with CD4+ T cells above 350cells/mm3
is less certain. Some clinical trials have shown improved
survival and improved surrogate markers [7, 21]. A
recent multicenter randomized clinical trial in sub-
Saharan Africa showed that mortality did not differ
between the delayed cART group and the early cART
group for HIV co-infected patients with CD4 + T cell
count of more than 350cells/mm3. This study also
showed that mortality was higher at 2 years of treatment
Table 1 Baseline characteristics among TB/HIV co-infected patients with CD4+ T cell count more than 350cells/mm3, for those initiated
on cART and those who were not on cART
Clinical characteristic No cART (n = 80) cART (n = 257)
n (%) n (%)
Sex a Male 41 (51) 106 (41)
Female 36 (49) 147 (57)
TB Microscopy Sputum smear positive 23 (29) 43 (17)
Sputum smear negative 30 (38) 136 (53)
Extra pulmonary 21 (26) 43 (17)
Not stated 6 (8) 35 (14)
Functional state Healthy, able to work 30 (38) 103 (40)
Ill, able to work 9(22) 43 (17)
Unable to work 6 (8) 13 (5)
Unknown 35 (44) 98 (38)
Median (Interquartile range)
Age, years 35 (28, 39) 36 (30, 44)
CD4+ T cell count, cells/mm3 465 (391, 580) 468 (397, 611)
Hemoglobin, mg/dl 11 (10, 14) 12 (10, 13)
Weight, kg 54 (45, 65) 54 (46, 54)
a Sex was not recorded in 7 participants
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Fig. 2 Kaplan Meier survival analysis for entire cohort and propensity score analysis cohort. a Entire cohort (cART: n = 257; no cART: n = 80).
b Propensity score generated cohort (n = 132)
Table 2 Adjusted Hazard ratios for overall cohort and propensity score matched cohort using Cox proportional hazards model
Overall cohort (n = 337) Propensity score matched cohort ( n = 132)
………………… Hazard ratio (95 % CI)………………………
cART Yes 0 · 22 (0 · 09, 0 · 52) 0 · 37 (0 · 15, 0 · 93)
No 1 · 0 1 · 0
Cotrimoxazole Yes 0 · 03 (0 · 01, 0 · 15) 0 · 09 (0 · 02, 0 · 43)
No 1 · 0 1 · 0
TB cure Yes 0 · 34 (0 · 16, 0 · 74) 0 · 28 (0 · 12, 0 · 68)
No 1 · 0 1 · 0
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for patients on cART [11]. The reasons for these divergent
results are unclear.
In our study, Cotrimoxazole prophylaxis was an inde-
pendent predictor of death and lowered the risk of death
by 90 %. The effect of Cotrimoxazole in reducing mor-
tality was consistent with findings of previous studies
[22, 23]. Provision of Cotrimoxazole is a minimum
standard of care for TB-HIV collaborative activities in
Zambia [16]. However patients who were on cART were
more likely to be on prophylaxis than those who were
not on cART. The difference in Cotrimoxazole prophy-
laxis coverage may be due to the difference in the quality
of care between the two groups.
Our study showed that cART was effective in reducing
mortality within the context of an existing health system.
The study offers a different perspective on the problem
of when to start cART since it is population based and
estimates the individual effectiveness of cART as op-
posed to efficacy, [15] in TB patients with CD4+ T cell
count above 350 cells/mm3. It also provides a pragmatic
answer to the question of whether cART is beneficial in
TB patients with higher CD4+ count in the context of
clinical care.
Inferences about the benefit of cART in this study are,
however, constrained because of confounding by indica-
tion and the differential loss to follow-up between those
started on cART and those who did not start. As for
confounding by indication, this may occur when patients
receive treatment based on clinical need, patient prefer-
ence, or severity of disease. In this analysis, we presumed
that patients treated with cART differed in prognosis
compared to patients not treated with cART. We ad-
justed for confounding by indication by performing a
propensity score analysis and confirmed the findings of
the main analysis. Patients on cART were more likely to
be on cotrimoxazole prophylaxis as compared to those
who were not initiated on cART. This imbalance may
explain survival differences in a crude analysis, but when
matching by propensity score, the proportion on cotri-
moxazole was balanced between groups and the propen-
sity score analysis confirmed that cotrimoxazole was an
independent determinant of survival in these patients
and did not attenuate the effect of cART.
As for bias due to loss to follow-up, we observed greater
loss to follow-up among the patients not receiving cART. If
the reasons for the losses were correlated with death, then
there may be a bias in favor of the cART. We suspect a se-
lection bias in this study because in cohort studies from
sub-Saharan Africa, a large proportion of those lost to
follow-up had died [24]. Since we were unable to ascertain
mortality among those who were lost to follow-up, we per-
formed a sensitivity analysis that explored the effect of two
extreme scenarios on the results. Regardless of the scenario,
the beneficial effect of cART on survival was still evident.
Although we cannot estimate the effect of cART precisely
using sensitivity analysis, we are confident that the true
value of the effect of cART lies between these two extremes.
As for information bias, we did not measure serial
CD4+ T cell counts during follow-up, so we are not able
to account for the time-dependent effect of the loss of
cellular immunity as the CD4+ T cell count declined. If
there is a differential decline between treated and un-
treated patients, then there would be a possible meas-
urement bias. Finally, previous studies have shown that
weight and height are drivers of mortality in patients
with TB [24, 25]. Although weight was measured regu-
larly in the clinics, height was not, so we were not able
to adjust for body mass index in the analysis.
Despite its limitations, our study provides evidence in
support of starting cART among HIV seropositive TB
patients with preserved immune function, as measured
by CD4 + T cell count. It shows the benefit offered by
cART and cotrimoxazole in the select group of TB-HIV
co-infected patients with preserved immunity.
Conclusion
In conclusion, starting cART during TB treatment com-
pared to no cART during TB treatment prolongs the
survival of HIV-infected TB patients with CD4+ T cell
counts above 350cells/mm3 in an African setting and is
associated with improved retention into care. Our find-
ings support he current recommendations by the WHO
to initiate cART in all HIV-infected TB patients regard-
less of the CD4+ T cell count. Further scale-up of cART
during TB treatment is needed to improve health out-
comes of HIV seropositive TB patients in Africa.
Additional file
Additional file 1: Survival times used to perform the survival analysis.
(CSV 3 kb).
Table 3 Adjusted hazard ratios under two scenarios of follow-up
using Cox proportional hazards model
Full follow-up scenario Early mortality scenario
….Hazard ratio (95 % CI)…
cART Yes 0 · 41 (0 · 18, 0 · 92) 0 · 28 (0 · 16, 0 · 49)
No 1 · 0 1 · 0
Cotrimoxazole Yes 0 · 06 (0 · 01, 0 · 26) 0 · 02 (0 · 01, 0 · 07)
No 1 · 0 1 · 0
TB cure Yes 0 · 38 (0 · 18, 0 · 84) 0 · 66 (0 · 38, 01 · 13)
No 1 · 0 1 · 0
Assumptions: Full follow up scenario—All patients who were lost to follow-up
survived until the end of the observation period (August 2012). Early Mortality
scenario—individuals lost to follow-up died within 90 days of the date
last seen
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